Each year, twenty million people worldwide receive a diagnosis of cancer And ten million dies. Fortunately, faced with this scourge, a therapeutic revolution is underway, and it is certainly made of lots of little mornings more than large evenings. This is what, this year again, emerged from the American Society of Clinical Oncology (ASCO) congress, which has converged for five days more than 40,000 international doctors and researchers in Chicago.
The star of this edition? Without question, immunotherapy, which has been asserting itself for ten years as the field where new drugs that have proven themselves in studies are the most numerous. Let us judge: they were the subject of three of the five studies presented during the prestigious Sunday meeting. The one that puts the projector on work that could change the situation for patients in the coming months, as long as pharmaceutical laboratories quickly obtain permits of market bets in the European Union and in the United States and reimbursements in each country.
